KDKrunal Detholia

Krunal Detholia

*This is an algorithmically generated author record based on publicly available information.

Krunal Detholia has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Hitesh Katariya

    Department of Pharmaceutics, SMT S. M. Shah Pharmacy College, Gujarat Technological University, Amsaran, Kheda, India

    2 shared publications
  • Mukesh Jadeja

    Department of Pharmaceutics, SMT S. M. Shah Pharmacy College, Gujarat Technological University, Amsaran, Kheda, India

    2 shared publications
  • Umang Varia

    Department of Pharmaceutics, SMT S. M. Shah Pharmacy College, Gujarat Technological University, Amsaran, Kheda, India

    2 shared publications
  • Amrutha A Mohandas

    Department of Pharmaceutics, Gujarat Technological University, Smt. S. M. Shah Pharmacy College, Amsaran, Kheda, Gujarat, India – 387130

    1 shared publication
  • Amrutha Mohandas

    Department of Pharmaceutics, SMT S. M. Shah Pharmacy College, Gujarat Technological University, Amsaran, Kheda, India

    1 shared publication
  • Hardi R Patel

    Department of Pharmaceutics, Gujarat Technological University, Smt. S. M. Shah Pharmacy College, Amsaran, Kheda, Gujarat, India – 387130

    1 shared publication

Latest Publications

  • Vilazodone Hydrochloride-Loaded Nanostructured Lipid Carrier In Situ Gel for Intranasal Nose-to-Brain Antidepressant Delivery

    by Khushi Shah, Rajeshkumar S. Palva, Mitali Patel, Musaratafrin Saiyed, Nisha Singh, Hardik Zala, Rajnikant M. Suthar, Krunal Detholia

    The Oral delivery of vilazodone hydrochloride (VLZ), a serotonin partial agonist–reuptake inhibitor for major depressive disorder,

  • Development and Characterization of Polymeric Idebenone Spherical Agglomerates by Quasi-emulsion Solvent Diffusion Technique

    by Umang R. Varia, Krunal K. Detholia, Hitesh B. Katariya, Mukesh B. Jadeja, Amrutha A Mohandas, Hardi R Patel

    Idebenone spherical agglomerates were prepared to improve micromeritics properties and solubility. The polymeric spherical agglomerates of Idebenone were developed by Quasi-emulsion solvent diffusion technique comprising three different solvents, methanol (good solvent), dichloromethane (bridging liquid) and water (poor solvent). A Pseudo ternary phase diagram was utilized to select and optimize the solvent system. The hydrophilic polymer PVP K30 was used as a medium stabilizer. The spherical agglomerates underwent a series of physicochemical assessments, including measurements of the angle of repose, Carr's index, Hausner's ratio, % yield, and shape. The optimized formulation exhibited a favourable angle of repose of 29.4°±0.034, and the % drug release after 30 minutes reached 83.11±3.8, surpassing all other concentrations. The optimized batch was further subjected to thorough analysis, encompassing Gas Chromatography to detect residual solvent levels and SEM, FT-IR, XRPD, drug content, and in-vitro dissolution studies. Subsequently, fast dispersible tablets were prepared using the optimized batch. For assessing stability, the optimized formulation underwent accelerated stability studies over a month at 40±2°C / 75±5% RH. These tests revealed negligible alterations in flowability, drug content, % yield, and drug release profile. The findings suggest that the polymeric spherical crystal agglomerates improve the micrometric properties and solubility of Idebenone.

  • Open Access

    Development and optimization of Ropinirole loaded self-nanoemulsifying tablets

    by Krunal Detholia, Amrutha Mohandas, Umang Varia, Mukesh Jadeja, Hitesh Katariya

    Background: The present research work aims to develop a Ropinirole-loaded self-Nanoemulsifying Drug Delivery system. Ropinirole has limited oral bioavailability due to substantial first-pass metabolism, which ultimately results in poor oral bioavailability and reduces plasma drug concentration and an overall reduction in therapeutic effects. Avoiding hepatic first-pass metabolism by increasing lymphatic uptake is the goal of the creation of the Ropinirole Self-NanoEmulsifying System. The solvent system for the liquid Self-NanoEmulsifying Drug Delivery System (SNEDDS) was optimized using Box-Behnken Design, where the concentration of oil(X1), surfactant (X2), and co-surfactant(X3) were taken as independent variables. The formulated liquid SNEDDS were then converted into solid SNEDDS by the adsorption method for improving patient compliance. Results: The obtained mean droplet size of the formulated SNEDDS was 96.71 nm, and the rate of emulsification was 22 s. Liquid SNEDDS was converted into solid SNEDDS using Syloid 244 FP as adsorbent. Scanning Electron Microscopy (SEM) study shows well-separated particles adsorbed on Syloid 244 FP. In vitro drug release studies show better release from solid and liquid SNEDDS when compared to pure suspension. Conclusions: Ropinirole-loaded SNEDDS can be a better option for reducing the extensive first-pass metabolism associated with Ropinirole.


  • Open Access

    A Novel Approach for the Treatment of Hypertension: Gastroretentive Microballoons of Atenolol

    by Krunal Detholia, Parth Patel, Umang Varia, Hitesh Katariya, Mukesh Jadeja

    The formulation of atenolol-loaded microballoons involved the use of Eudragit RS 100, HPMC K4 M as a polymer, and span 80 as a surfactant. The microballoons were prepared by an emulsion solvent diffusion (non-aqueous) using liquid paraffin, methanol, and dichloromethane as a processing medium. The Box-Behnken design was utilized to get optimized formulation using a concentration of HPMC K4 M (A), Concentration of Eudragit RS 100 (B), Concentration of surfactant (C), and stirring speed (D) as an independent parameter while, Particle size (Y1), entrapment efficiency (Y2) and %buoyancy (Y3) using as a dependent parameter. For the optimised formulation, the mean particle size was 85.878 ± 1.063 μm, entrapment efficiency was 92.26 ± 1.65%, and buoyancy was 89.19 ± 1.48% found. An image of the formulation taken using a scanning electron microscope (SEM) reveals discrete particles with a smooth surface texture, a hollow interior, a spherical shape, and a particle size of less than 200 μm. The FTIR study confirms there was no interaction between the drug and excipients. The in-vitro drug release study found that atenolol-loaded microballoons released the drug for up to 12 hours as compared to the pure drug. This was due to increasing the gastric residence time and absorption area in the stomach. The drug release kinetic study reveals that it follows the Higuchi model and the drug release mechanism was type II transport which was obtained from the Korsmeyer Peppas model. The stability study shows that there is no significant change in the optimized microballoons for 30 days as per ICH guidelines.